Epsilon Healthcare (ASX:EPN) said its unit, Epsilon Pharma, has been granted a renewal of its medicinal cannabis permit, according to a Tuesday Australian bourse filing.
The unit is now allowed to manufacture more quantities compared to previous permits, reflecting increased activities for the upcoming twelve months, the filing added.
The unit now also possesses an export licence and an import permit, per the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.